Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASALT: Tocilizumab in Esophageal Adenocarcinoma
NCT04554771Phase 2Active, not recruiting
- Sponsor
- University of Amsterdam
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab in esophageal adenocarcinoma (EAC) (4 arms), sponsored by University of Amsterdam. Primary endpoint: Pathological response to chemoradiotherapy according to the Mandard criteria at 34 months. Started Jan 2021; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT04554771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554771.